ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.

"CONFLICT OF INTEREST Saskia Hussung reports fees from Pierre Fabre and Incyte outside the submitted work. Smruthy Sivakumar is an employee at Foundation Medicine, Inc, a wholly owned subsidiary of Roche Holdings, Inc and Roche Finance Ltd, and has equity interest in an affiliate of these Roche entities (shareholder at Roche). Christian Britschgi reports Consulting or Advisory Role for AstraZeneca, Pfizer, Roche, Takeda, Janssen Cilag, and Boehringer‐Ingelheim, and Travel, Accommodations, Expenses from AstraZeneca and Takeda, all outside the submitted work. Ethan Sokol is an employee at Foundation Medicine, Inc, a wholly owned subsidiary of Roche Holdings, Inc and Roche Finance Ltd, and has equity interest in an affiliate of these Roche entities (shareholder at Roche). The institution of Holger Moch received research funding from Roche. Martin Zoche received research grants from F. Hoffmann‐La Roche AG and consultancy fees from Astra Zeneca and Bayer AG. Ralph M. Fritsch reports grants and personal fees from Pierre Fabre, Bayer, Merck, MSD, Astra Zeneca, Novartis and BMS outside the submitted work. No disclosures were reported from the other authors."

"The graphical abstract was created with BioRender.com. Open access funding provided by Universitat Zurich."